Trial Profile
An Exploratory Pilot Study of Nab-paclitaxel Based Induction Chemotherapy Followed by Response-Stratified Locoregional Therapy for Patients With Stage III and IV HPV-Related Oropharyngeal Cancer - the OPTIMA HPV Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Sep 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Carboplatin; Cisplatin; Fluorouracil; Hydroxycarbamide
- Indications Head and neck cancer; Human papillomavirus infections; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms OPTIMA
- 28 Aug 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2025.
- 08 Feb 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 31 May 2020 Results of long-term follow-up from this study and retrospective review of additional patients treated subsequently per OPTIMA outline (n=106) presented at the 56th Annual Meeting of the American Society of Clinical Oncology.